Lactate Metabolism in the Hypoperfused Critically Ill
Lactate Metabolism in Patientens With Hyperlactatemia-associated Metabolic Acidosis
1 other identifier
observational
20
1 country
1
Brief Summary
Investigating lactate metabolism in critically ill patients whom are hypoperfused by preforming metabolomics via liquid chromatography-mass spectrometry.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Sep 2022
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 13, 2022
CompletedStudy Start
First participant enrolled
September 15, 2022
CompletedFirst Posted
Study publicly available on registry
October 17, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2023
CompletedOctober 17, 2022
September 1, 2022
2 months
September 13, 2022
October 12, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Laktate levels in blood
Levels of lactate in the blood in relation to the key metabolites (secondary outcomes). Patients included will be testet daily during admission to intensive care whilst lactate is above 2 mmol/l and one more day while laktat is below.
Daily testing. Average time frame for the paticipants are 3 days (ranging from 1-10 days).
Secondary Outcomes (5)
Metabolomics using High Pressure Liquid Cromotografy (HPLC) and Mass Spectrometry (MS)
Two seperate days. One in december 2022 and one in approximately february 2023 (when all patientens are included and all samples are collected).
Mortality
Admission time ranges up to 6 months.
Pyruvate and hydroxybuterate concentration in blood and urine
Two seperate days. One in december 2022 and one in approximately february 2023 (when all patientens are included and all samples are collected).
Near-infrared spectroscopy (NIRS)
Daily testing. Average time frame for the paticipants are 3 days (ranging from 1-10 days).
Peripheral perfusion index (PPI)
Daily testing. Average time frame for the paticipants are 3 days (ranging from 1-10 days).
Study Arms (1)
Main group
All patients included
Interventions
Eligibility Criteria
A broad spectrum of patients will make up for the population of the study. These are critically ill adults who are admitted to the intensive care unit of Hvidovre Hospital.
You may qualify if:
- Diagnosed with sepsis/septic shock or severe heart failure.
- Clinical and paraclinical signs of hypoperfusion in relation to abovementioned diagnosis.
- Metabolic acidosis with s-lactate equal-to-or-above 4 mmol/l.
- Incapacitated
You may not qualify if:
- Only regional hypoperfusion such as a leg.
- Receiving intravenous lactate as part of treatment.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Copenhagenlead
- Hvidovre University Hospitalcollaborator
Study Sites (1)
Hvidovre University Hospital
Hvidovre, Capital Region, 2650, Denmark
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 13, 2022
First Posted
October 17, 2022
Study Start
September 15, 2022
Primary Completion
November 1, 2022
Study Completion
January 1, 2023
Last Updated
October 17, 2022
Record last verified: 2022-09